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A B S T R A C T
Scleritis is a sight-threatening inflammation characterized by severe pain and redness of the eye. It can cause
blindness by severe complications like scleral and corneal necrosis, keratitis, and uveitis. The pathogenesis of
scleritis is largely unknown due to a combination of the rarity of the disease, the little available human tissue-
based research material, and the lack of animal models. The immune system is assumed to play a crucial role in
the pathogenesis of scleritis. Multiple clues indicate probable antigenic stimuli in scleritis, and the involvement
of matrix metalloproteinases in the destruction of scleral tissue. In this article we review the current insights into
the pathogenesis of scleritis, and we suggest new hypotheses by implementing knowledge of systemic auto-
immune disease pathogenesis. Understanding the pathogenesis of scleritis is crucial to improve the clinical
management, as well as to find novel treatment modalities.
1. Introduction
Scleritis is an uncommon inflammation of the outer coat of the eye
referred to as sclera. The inflammation is generally characterized by
intense pain of the affected eye, and in severe cases may lead to visual
loss or even blindness (Watson and Hayreh, 1976; Wieringa et al.,
2013). Although scleritis is considered to be relatively rare, exact
numbers on incidence and prevalence are lacking (Okhravi et al., 2005;
Sainz de la Maza et al., 2012a). A crude estimate of the incidence rate of
scleritis is 4 per 100.000 person years. Scleritis occurs more often in
females than in males, and commonly affects the middle-aged popula-
tion (Homayounfar et al., 2013). Causes of scleritis are varied with up
to 50% of cases being associated with systemic autoimmune diseases,
including rheumatoid arthritis, ANCA-associated granulomatosis with
polyangiitis (GPA), and relapsing polychondritis. (Sainz de la Maza
et al., 2012b; Watson and Hayreh, 1976). Less frequent, scleritis is
caused by local or systemic infection, trauma, specific drugs, irradia-
tion, or malignancy. This review focusses on idiopathic and immune
mediated scleritis. The exact clinical impact is not precisely known, but
is presumably very high. Scleritis can become resistant to various
treatment modalities, resulting in untreatable pain, and severe ocular
complications. In rare cases, scleritis may ultimately require enuclea-
tion. As a consequence, scleritis can significantly affect a patient's
quality of life (Akintayo et al., 2019; Sharma et al., 2019).
The classification of scleritis by Watson and Hayre from 1976 is still
being used. This classifies scleritis cases into anterior or posterior, and
further into diffuse, nodular, or necrotizing scleritis based on clinical
findings (Watson and Hayreh, 1976). The clinical presentation of
scleritis, its systemic manifestations and outcomes have been well de-
scribed (Abd El Latif et al., 2018; Ando et al., 2019; Lane et al., 2018;
Sainz de la Maza et al., 2012b; Tanaka et al., 2018; Watson Peter G and
Jaypee, 2012; Wieringa et al., 2013; Yang et al., 2018). In contrast, the
pathogenesis of scleritis represents an underexposed area of interest.
Possible reasons include the relative rarity of the disease, the lack of
animal models, and scarcity of available human tissue-based research
material.
A crucial role of the immune system in the pathogenesis of scleritis
is very likely. Several hypotheses have been proposed, including both
cell-mediated and humoral, antibody-mediated, mechanisms. New in-
sights in the pathogenesis of systemic autoimmune diseases, that are
associated with the development of scleritis, may be beneficial to fur-
ther elucidate that of scleritis (Wakefield et al., 2013b; Watson and
Romano, 2014; Watson and Young, 2004). At present though, the pa-
thogenesis of this potentially blinding disorder is poorly understood. An
increased insight in the pathogenesis of scleritis is expected to improve
clinical outcome and enrich the potential for novel treatment
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modalities.
In this article we will review the current insights in scleritis with
emphasis on its pathogenesis, and we will discuss relevant current and
potential future lines of research on scleritis.
2. The anatomy and components of the sclera
Sclera derives from the Greek word “σκλƞρος’’ meaning “hard’’, and
comprises five-sixth of the eye's surface. The average thickness is ap-
proximately 0.7 mm, which increases near the optic nerve, and de-
creases towards the recti muscles. The sclera is continuous with Tenon's
capsule. This capsule encloses the recti muscles, and forms a muscle
pulley for the extraocular muscles. Underneath Tenon's capsule is the
episclera, a thin and densely-vascularized layer of connective tissue.
The innermost layer of the sclera blends into the choroidal stroma and
is called the lamina fusca. The nourishment of the scleral stroma is
provided by the choroidal and episcleral vasculature. The choroidal
vascular network consists of anastomoses of superficial and deep
choroidal end arteries, which causes a sluggish or oscillating blood flow
(Meyer, 1988; Watson and Romano, 2014). The episcleral vascular
network derives its blood supply from the anterior- and posterior ciliary
artery (Watson and Young, 2004). Blood vessels and nerves transverse
the scleral stroma through perforating canals or emissaria. No capillary
network is present in the sclera. The nerve supply of the sclera is rich,
and consists of short- and long ciliary nerves (Wakefield et al., 2013b;
Watson and Young, 2004).
The scleral stroma obtains its resilience and strength from bundles
of irregular-aligned collagen fibrils grouped into dense lamellae. This
arrangement, in contrast to the parallel-aligned collagen fibrils in the
cornea, determines the sclera's non-transparency. Elastic fibers, fibro-
blasts, few macrophages, and dendritic cells intermingle with the col-
lagen fibers. The scleral stroma consists mainly of collagen type I.
Thereby, small amounts of collagen type II-XV, XVIII and XIX are pre-
sent (Watson and Young, 2004; Young et al., 2004). Elastic fibers re-
present approximately 2% of the human sclera, and are located pre-
dominantly in the lamina fusca. In the extracellular matrix of the scleral
stroma, proteoglycans (PG) have been identified (Coster and Fransson,
1981; Wakefield et al., 2013b; Watson and Young, 2004). Mainly dec-
orin, biglycan and small amounts of the large PG aggrecan (similar to
the well-known cartilage aggrecan) were reported (Ward et al., 1987).
The PGs encircle and connect collagen fibers (Watson and Romano,
2014). Especially decorin has been proven to be crucial in adhesion of
collagen, as the reduction of decorin was found to be associated with
development of myopia in marmosets (Watson and Romano, 2014).
Fibroblasts are crucial to maintain the scleral structure (Wakefield
et al., 2013b). Many similarities between scleral and cartilage tissue
have been reported. Despite the fact that sclera is mainly characterized




Various ocular inflammatory disorders are associated with specific
human leucocyte antigen (HLA) alleles. (Goverdhan et al., 2005). The
HLA gene complex, located at chromosome 6, encodes HLA class I (A, B
and C) and HLA class II (DR, DP and DQ) molecules. The most promi-
nent function of the HLA complex is the presentation of peptide anti-
gens to T-cells (Goverdhan et al., 2005). Association between HLA al-
leles and disease indicates the involvement of (auto)immune
mechanisms in disease pathogenesis. So far, besides a possible asso-
ciation with HLA-B27 found in five patients, no genetic predisposition
based on HLA association has been identified in scleritis (Anshu and
Chee, 2007; Okhravi et al., 2005; Watson and Young, 2004). Rheu-
matoid arthritis, in contrast, often observed in combination with
scleritis, is clearly associated with an allele of HLA-DR4 and HLA-DR1,
as well as with alleles of HLA-DR13 and HLA-DR15 (Karami et al.,
2019). The HLA-DR4 allele was also found to be associated with re-
lapsing polychondritis (Terao et al., 2016), while the HLA-DR15 allele
was also found to be associated with systemic lupus erythematosus
(SLE) and ANCA-associated vasculitis (Javinani et al., 2019;
Rahmattulla et al., 2016). In SLE, besides HLA-DR15, other alleles of
HLA-DR were found to more prevalent. Thereby, a gene polymorphism
in HLA-DP, which was also found in rheumatoid arthritis, was im-
plicated to be associated with SLE (Huang et al., 2018; Javinani et al.,
2019). Interestingly, the HLA-DR15 allele was found to be a possible
predisposing factor for corneal ulceration in response to inflammation,
however this was not typical for scleritis (Watson and Young, 2004).
3.2. Non HLA-association
A single study investigated non-HLA gene susceptibility loci in a
large cohort of 432 patients with non-infectious scleritis. The authors
focused on two genes, the cytotoxic T lymphocyte-associated antigen-4
(CTLA4) and the protein tyrosine phosphatase non-receptor type 22
(PTPN22). Both genes regulate the control of T-cell activity, and poly-
morphisms were previously reported to be involved in the development
of autoimmune responses. A CTLA4 single nucleotide polymorphism
(SNP) was found to be a predisposing factor for posterior scleritis, and a
risk association of a specific PTPN22 haplotype and scleritis was found
in this large cohort (Li et al., 2019). PTPN22 and CTLA4 were also
reported as susceptibility loci in rheumatoid arthritis. Genome wide
association studies were repeatedly performed in rheumatoid arthritis,
in which additional SNPs in genes were discovered, including TRAF1,
STAT4, IRF5, CCR6, IL23R and PAD14 (Karami et al., 2019). Some of
the previously mentioned gene loci were also associated with GPA and
SLE (Deng and Tsao, 2017; Relle et al., 2016). The majority of asso-
ciated gene loci were implicated to be involved in antigen presentation
and B-cell function (Karami et al., 2019). The relevance of these genes




Anti-CCP Anti-cyclic citrullinaded peptide
Anti-MCVAnti-mutated citrullinated vimentin
cANCA Anti-neutrophil cytoplasmic antibody, cytoplasmic
CTLA4 Cytotoxic T lymphocyte-associated antigen-4
FAG Fluorescein angiography
GPA Granulomatosis with polyangiitis
HLA Human leucocyte antigen
ICG Indocyanine green angiography
IFN-γ Interferon gamma
MHC Major histocompatibility complex
MMP Matrix metallo proteinase
OCT Optical coherence tomography
pANCA Anti-neutrophil cytoplasmic antibody, perinuclear
PG Proteoglycans
PTPN22 Protein tyrosine phosphatase non-receptor type 22
SLE Systemic lupus erythematosus
SNP Single nucleotide polymorphism
TIMP Tissue inhibitor of matrix metalloproteinase
UBM Ultrasound biomicroscopy
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4. Histo- & immunopathology in scleritis
Histopathological examinations of scleral tissue from patients with
scleritis are scarce. Biopsies in scleritis are often contraindicated, as any
kind of surgery may induce or aggravate scleral inflammation. A ma-
jority of the limited information arises from advanced scleritis cases,
specifically from enucleated eyes during the end stage of the disease.
Thereby, the available findings demonstrate a large heterogeneity.
4.1. Subtypes
Based on histopathological findings, several subtypes of scleritis can
be distinguished. In scleritis associated with systemic autoimmune
diseases, the necrotic scleral areas are accompanied by zonal granulo-
matous inflammation with polymorpho-nuclear granulocytes and
macrophages. The necrotic areas are predominantly surrounded by
CD20+ B-cells and CD138+ plasma cells, and are sometimes accom-
panied by vasculitis. Scleritis without an associated systemic disorder
showed a non-specific chronic leucocyte infiltration without necrosis,
characterized by CD3+ T-cells, plasma cells and occasional B-lymphoid
follicles with few macrophages, and polymorpho-nuclear granulocytes
(Rao et al., 1985; Riono et al., 1999; Usui et al., 2008). Considerable
overlap between these proposed groups on histopathological findings
was noted (Hankins and Margo, 2019). Interestingly, a recent study
showed that probable or definite IgG4 related disease could be observed
in five of fifteen idiopathic scleritis cases. Providing a possible subtype
in the group of idiopathic scleritis patients (Karim et al., 2017a).
4.2. Immune complexes
Accumulation of immune complexes of IgM and IgG type was re-
peatedly described, however their origin and exact role are unknown
(De la Maza and Foster, 1991; Díaz-Valle et al., 1998; Hembry et al.,
1979; Lye Pheng et al., 1991; McCluskey et al., 1985; Wakefield et al.,
2013a). The deposition of immune complexes can exaggerate in-
flammatory microangiopathy, in which the complement system seems
likely to be involved. C1q was particularly found in the anterior sclera
of healthy donors, while other complement factors were present in the
whole sclera (Brawman-Mintzer et al., 1988, 1989). Inflammatory mi-
croangiopathy may contribute to the initiation and maintenance of
scleral inflammation and damage. The damaged sites of the vascular
endothelium were noted to express HLA-DR, which is a HLA class II cell
surface receptor (Díaz-Valle et al., 1998; Hankins and Margo, 2019;
Watson and Young, 2004). The expression of class II HLA antigens is not
expected in healthy scleral tissue, as normally only professional antigen
presenting cells express HLA class II. A similar finding was found in
inflamed joints of patients with rheumatoid arthritis, where fibroblasts
expressed high levels of HLA-DR antigens. The expression of the HLA
class II in these tissues may hypothetically be induced by inflammatory
cytokines (Goverdhan et al., 2005).
Fig. 1. Overview of the main immunopathological mechanisms of several autoimmune versus autoinflammatory ocular- and systemic diseases. At present it is
unclear where scleritis is situated in this overview. Arguments for scleritis to be autoimmune mediated are present. However, specific autoantibodies or self-antigens
are hardly elucidated. Relapsing polychondritis also remains to be classified. In this image, based on the image of McGonagle et al., the list of diseases is obviously not
complete (McGonagle and McDermott, 2006).
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4.3. Additional findings
Elevated expression of adhesion molecules (CD11a/18: lymphocyte
function associated antigen 1, LFA-1, and CD54: intercellular adhesion
molecule 1, ICAM-1) was described. These adhesion molecules could
enhance the infiltration of lymphocytes, and may contribute to the
ongoing inflammation. Fas (CD95) and FasL (CD95L), specific markers
for apoptosis, were abundantly present in biopsies of necrotizing
scleritis. Increased apoptosis of T-cells could indicate local activation of
T-cells. However, it is not yet known which cells show increased mar-
kers for apoptosis (Díaz-Valle et al., 1998; Levy-Clarke et al., 2009;
Wakefield et al., 2013a).
4.4. Necrosis
Two possible explanations for the extensive necrosis that occurs in
some scleritis cases have been noted. At first, necrosis can be a result of
ischemia. Ischemia is either caused by occlusive vasculitis, or by in-
sufficient vascular flow resulting from inflammation in a preexistent
low vascularized tissue. Secondly, necrosis can be a result of the
breakdown of collagen fibrils and its surrounding proteoglycan matrix
by proteolytic enzymes. Histopathological images of necrotic sclera
show swelling and unraveling of collagen fibrils, as well as an increased
distance between the fibrils. Subtle changes were observed in areas
around necrosis, consisting of activated fibroblasts. This supports the
explanation that destruction of the scleral matrix, by proteolytic en-
zymes, precedes the development of necrosis (Sevel, 1968; Watson and
Young, 2004; Young et al., 1988; Young and Watson, 1984a, b).
5. Autoimmunity in scleritis
The hypothesis of an autoimmune origin of scleritis was already
proposed in the early 80s by Wilhelmus et al., and has been repeatedly
suggested (Aragaki et al., 2007; James et al., 1985; Wakefield et al.,
2013a, b; Watson and Young, 2004).
5.1. Autoimmunity versus autoinflammatory
Autoimmune diseases are characterized by the production of spe-
cific autoantibodies and/or the presence of auto-reactive T-cells. The
primarily involved immunological mechanisms belong to the adaptive
immune system (McGonagle and McDermott, 2006). The pathogenic
role of the involved autoantibodies is often unknown. For example
antinuclear antibodies (ANA), present in SLE, are also present in
healthy subjects (Marin et al., 2009). In autoinflammatory diseases,
such as Behçet's disease, Crohn disease or sarcoïdosis, a self-directed
inflammation of predominantly the innate immune system occurs
(McGonagle and McDermott, 2006; ten Berge et al., 2018). The ma-
jority of scleritis cases is associated with autoimmune diseases, while a
minority is associated with previously mentioned autoinflammatory
diseases. However, it is unknown so far if the innate or the adaptive
immune system plays a predominant role in idiopathic scleritis (Fig. 1).
(Akpek et al., 2004; Watson and Hayreh, 1976)
5.2. Autoantibodies
In idiopathic scleritis, the presence of antibodies directed against two
sclera-specific antigens was noted only once. The antigens had a mole-
cular weight of 15 kDa and 45 kDa (Aragaki et al., 2007). This study was
conducted in two patients and the presence of auto-antibodies is not yet
confirmed in a larger cohort (Wakefield et al., 2013b). Specific auto-
antibodies are clearly involved in the pathogenesis of some of the sys-
temic autoimmune diseases associated with scleritis, such as GPA, SLE
and rheumatoid arthritis. In GPA, the anti-neutrophil cytoplasmic auto-
antibodies (mostly cANCA: an antibody against proteinase 3, and some-
times pANCA, an antibody against myeloperoxidase) are prominently
involved in the development of vasculitis. In SLE, anti-dsDNA antibodies
are clearly associated with renal pathology (lupus nephritis). In rheu-
matoid arthritis, rheumatoid factor and antibodies against collagen, fi-
bronectin, keratin and especially citrullinated protein (ACPA, including
anti-CCP and anti-MCV) have been found, in which the latter is predictive
for more severe joint damage. (Margo and Harman, 2016).
5.3. Candidate antigens
Knowledge of the pathogenesis of the aforementioned systemic
diseases might help to clarify that of scleritis, because of resemblances.
For example, collagen and the extracellular matrix proteoglycans are
commonly found in both joint, tissue involved in rheumatoid arthritis,
and sclera (Orr et al., 2017; Watson and Young, 2004). Human scleral
cells share common characteristics with chondrocytes in joints, such as
the potential to produce collagen type II when stimulated with specific
cytokines (Seko et al., 2008). In addition, histopathological findings
disclose resemblances between synovitis and scleritis (Orr et al., 2017;
Wakefield et al., 2013b; Watson and Young, 2004; Young et al., 1988;
Zierhut et al., 1994). Interestingly, high levels of anti-collagen type II
antibodies were found in synovial fluid of patients with rheumatoid
arthritis and were even suggested to initiate arthritis (Nandakumar,
2010; Rowley et al., 2008). Anti-collagen type II antibodies were like-
wise found in relapsing polychondritis (Lekpa and Chevalier, 2018;
Sainz-De-La-Maza et al., 2016). Candidate antigens in scleritis thus may
include collagens, proteoglycans, and other extracellular matrix pro-
teins, which are abundantly present in scleral tissue (Young et al.,
2004). Another possibility is the occurrence of novel antigenic epitopes
in damaged scleral tissue.
The process that initiates the autoimmune cascade in scleritis, as
well as in systemic disorders, is so far not known. In addition to genetic
and immunological factors, environmental factors were suggested to be
involved, including trauma and bacterial or viral infections (Wakefield
et al., 2013b; Watson and Young, 2004). In several autoimmune dis-
eases, molecular mimicry is suggested to facilitate autoimmunity. In
this situation, autoreactive T-cells and/or autoantibodies are expanded
as a result of stimulation by an exogenous molecule with cross-reactive
epitopes to that of a self-antigen (Cusick et al., 2012). The cross re-
activity of C. Jejuni and motor neuron axons in Guillain Barré syndrome
is well-known. Also in rheumatoid arthritis and SLE cross reactivity of
microorganisms and human proteins have been found to be involved in
the pathogenesis (Rojas et al., 2018). This explanation is not exclusive,
and the role of molecular mimicry in scleritis has not yet been proven.
6. Animal studies
The restricted knowledge on the pathogenesis of scleritis is partly
due to the limited number of animal studies available. To the best of our
knowledge, there are three successful laboratory animal models on
scleritis and only a few histopathological studies on scleritis in dogs.
6.1. Histopathological evaluations in animals
Histopathological findings in dogs are comparable to the histo-
pathological studies of affected scleral tissue in humans. Enucleated
eyes of dogs affected by scleritis were characterized by granulomatous
inflammation, macrophages expressing class-II HLA, CD3+ T-cells and
IgG positive plasma cells. Perivascular depositions of IgG-antibodies
were found in some cases (Day et al., 2008; Grahn and Sandmeyer,
2008). Additionally, Denk et al. showed an altered staining pattern with
Masson's trichrome stain of damaged collagen in scleritis tissue. This
has also been observed in animals affected by a collagen disorder, and
indicates damage of collagen fibers. The majority of dog breeds de-
scribed in histopathological evaluations of scleritis have a genetic
predisposition to autoimmune diseases (e.g. the English Cocker Spa-
niel). (Kennedy et al., 2006).
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6.2. Animal models
The first experimental animal model for scleritis consisted of oval-
bumin sensitized rabbits, and described the development of scleral and
adjacent corneal inflammation after injection of ovalbumin into the
limbus. The experiment was performed to describe clinical progression,
and the histopathology of the scleral infiltrate (Hembry et al., 1979). A
murine model for human autoimmune diseases (MRL/Mp-lpr/lpr mice)
reported the development of scleritis at older age in multiple mice (Jabs
et al., 1985). The lpr/lpr phenotype results from an autosomal re-
gressive mutation in the Fas (CD95) gene causing massive benign
lymphadenopathy. This is seen in autoimmune lymphoproliferative
disease as well, providing an argument for autoimmunity in scleritis.
These MRL/Mp-lpr/lpr mice also showed increased Il-1β and MMP-1
concentration at the cornea due to their genetic basis (Okamoto et al.,
2004). Finally, another murine model of anterior scleritis was estab-
lished by modifying a collagen-induced autoimmune arthritis model.
Mice were sensitized with collagen type II, and consequently developed
anterior scleritis with features of an immune complex deposition dis-
order (Taniguchi et al., 2015). The presence of collagen type II in scleral
tissue, although minimal, may indicate an antigen specific immune
reaction.
7. Role of matrix metalloproteinases
Scleral necrosis or scleromalacia is the most severe complication of
scleritis (Fig. 2). The prevalence of necrosis of scleral and/or peripheral
corneal tissue in scleritis varies from 6 to 28%. Matrix metalloprotei-
nases (MMPs) probably play a crucial role in the development of ne-
crosis, similarly to tissue destruction elsewhere in the body (Di
Girolamo et al., 1997; Wakefield et al., 2013b; Watson and Young,
2004).
The human body contains multiple functional proteolytic enzymes
(including MMPs), which are capable of degrading (extracellular) ma-
trix proteins (Rose and Kooyman, 2016). MMPs represent a family of
enzymes capable of degrading collagen. Physiologically MMPs are ef-
fective mediators of tissue remodeling, wound healing and embryologic
development (Wakefield et al., 2013b; Watson and Hayreh). Disbalance
in the level of MMPs and their inhibitors, the tissue inhibitors of matrix
metalloproteinase (TIMPs) may lead to extensive degradation of col-
lagen (Wakefield et al., 2013b). For example, in cancer MMPs are
needed for tumor progression and play a role in development of me-
tastases (Gonzalez-Avila et al., 2019).
7.1. Evidence of MMPs in scleritis
A disbalance of MMPs and their inhibitors is suggested to occur in
scleritis. The level of the pro-inflammatory cytokine TNFα in tear fluid
was found to be increased in patients with necrotizing scleritis. TNFα is
a potent inducer of MMP production by scleral fibroblast (Fig. 3) (Seo
et al., 2006). In addition, TIMP-1, the natural inhibitor of MMPs, was
found to be less expressed in diseased scleral tissue (Di Girolamo et al.,
1998). In the scarce reports on scleritis, specifically MMP-3 and -9 were
found to be increased in scleral tissue and tears of patients with ne-
crotizing scleritis (Fig. 3) (Di Girolamo et al., 1997; Seo et al., 2006;
Young et al., 2004). This excess of MMPs could induce collagen de-
gradation, which is seen by unraveling of collagen in histopathological
images. Nevertheless, the exact pathophysiological process of scleral
necrosis is not yet clarified.
7.2. Research in rheumatoid arthritis
In contrast to the scarce reports on scleritis, extensive research on
MMPs in the destruction of cartilage has been performed in rheumatoid
arthritis. Collagen in cartilage tissue is degraded by the actions of MMP-
1, -8, -9, -13 and −14, whereof MMP-1 and MMP-13 were believed to
be most important in cleaving collagen type II. Collagen type I, which is
the main component of sclera, is most actively destroyed by MMP-8 in
rheumatoid arthritis (Burrage et al., 2006). MMP-14 was proposed to
regulate the destruction of collagen, and to control fibroblast-induced
angiogenesis in inflamed joints (MacNaul et al., 1990; Sabeh et al.,
2010; Wakefield et al., 2013a). Further, A disintegrin and metalloprotei-
nase with thrombospondin motifs (ADAMTS), a more recently discovered
member of the MMPs, is also involved in the destruction of cartilage in
rheumatoid arthritis. The ADAMTS not only degrade collagen, but also
degrade the PG aggrecan (ADAMTS-1, -4, -5, -8, -9 and -15) (Burrage
et al., 2006). Finally, non-collagen matrix proteins in rheumatoid ar-
thritis may also be degraded by the stromelysins (MMP-3, -10 and −11)
(Burrage et al., 2006; Rose and Kooyman, 2016). Aggrecan and other
matrix molecules are also found in scleral tissue and in consequence
represent potential targets for these proteases in scleritis.
8. Biomarkers in scleritis
A biomarker is defined as a substance, structure or a process, that
either influences or predicts incidence and/or outcome of disease. A
biomarker needs to be objective and quantifiable (Strimbu and Tavel,
2010). Considering scleritis, previous research has focused on bio-
markers predicting the development of systemic autoimmune diseases
in patients with scleritis. Research focusing on biomarkers predicting
the development, severity and/or prognosis of scleritis remains very
limited.
8.1. Possible biomarkers for diagnosis of systemic diseases in scleritis
Systemic autoimmune diseases are more prevalent in patients with
scleritis, compared to the general population (Wieringa et al., 2013).
The systemic autoimmune disease manifests either prior to, or after the
onset of scleritis. Useful screening markers to diagnose systemic auto-
immune diseases are cANCA an pANCA for systemic vasculitis, RF and
ACPA (mostly anti-CCP) for rheumatoid arthritis, and ANA and anti-
dsDNA for SLE (Akpek et al., 2004; Lin et al., 2008; Mills et al., 1991;
Orr et al., 2017; Wakefield et al., 2013b). Furthermore, increased serum
IgG4 can indicate IgG4 related disease, belonging to the systemic au-
toinflammatory diseases (Karim et al., 2017b). However, in a great
percentage of patients with scleritis no cause can be established. In
addition, predicting scleritis in patients with systemic diseases, is not
yet possible.
Fig. 2. A 72-year old patient with granulomatosis with polyangiitis (GPA) de-
veloped severe scleral thinning following strabismus surgery.
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8.2. Possible biomarkers predicting the development, severity and prognosis
of scleritis
Several clinical factors are associated with poor prognosis, such as
bilateral involvement, necrosis, longer durations of symptoms at diag-
nosis, and the presence of any systemic autoimmune disease (Wieringa
et al., 2013). Hereof, scleritis in patients with GPA or relapsing poly-
chondritis was commonly found to be severe, while scleritis in patients
with rheumatoid arthritis was usually moderate, and in patients with
SLE was found to be predominantly mild (Sainz-De-La-Maza et al.,
2016a; Sainz de la Maza et al., 1995). Furthermore, positive ANCA's
were noted to be associated with severe scleritis, most probably due to
their specificity for GPA (de Sousa et al., 2011; Hoang et al., 2008). The
prognostic value of general blood inflammation markers, such as C-
reactive protein or erythrocyte sedimentation rate, is so far not known
in scleritis. Previous research did found increased levels of IL-1b, TNFα,
IL-22, MMP-9, and IL17 expressing T-cells in blood and/or tear fluid of
patients with active scleritis (Palexas et al., 1992; Sainz-de-la-Maza
et al., 2016b; Seo et al., 2006). Despite the yet unknown prognostic
value, they are potential biomarker candidates. TNFa and IL-22 are
produced by Th17 cells, which can be expanded by IL-2, and inhibited
by IFNy. Regarding this, one can implicate the role of TH17 cells and IL-
22 in the pathogenesis of scleritis. Increased serum levels of IL-22 were
also reported in rheumatoid arthritis and associated with an erosive
type (Leipe et al., 2011). Furthermore in rheumatoid arthritis, IL-1b
showed the ability to stimulate cartilage degradation (Palexas et al.,
1992).
Since the pathogenesis of scleritis is far from elucidated, the iden-
tification of useful biomarkers is challenging. Obviously, caution is
required in the interpretation of potential biomarkers, and their vali-
dation in clinical settings is necessary. The so far identified biomarkers
only partly provide reliable, and clinically meaningful information for
patients with scleritis. This underlies the urgent need for the develop-
ment of novel biomarkers.
9. Imaging in scleritis
Imaging of inflamed scleral tissue in scleritis has a crucial role in the
diagnosis of especially posterior scleritis. Furthermore, imaging may
contribute to further understand the pathogenesis of scleritis, especially
with current rapidly evolving imaging modalities. Optical coherence
tomography (OCT), B-scan ultrasonography (US), ultrasound biomi-
croscopy (UBM), fluorescein angiography (FAG), indocyanine green
angiography (ICG), and magnetic resonance imaging (MRI) represent
mostly studied imaging techniques in scleritis (Okhravi et al., 2005;
Watson and Romano, 2014; Zur et al., 2016). Using OCT and UBM, the
structure of the anterior sclera can be accurately imaged, while FAG
and ICG show the (epi)scleral vasculature (Nieuwenhuizen et al., 2003;
Watson and Romano, 2014). The posterior sclera, including vascu-
lature, is well imaged using US, MRI, OCT and ICG.
Fig. 3. Overview of the destructive potential of matrix metalloproteinases (MMPs).
An undifferentiated stimulus may lead to the production of pro-inflammatory cytokines. These cytokines (including IL-1, TNFα, IL-6 and IL-17) can activate the
production of MMPs by fibroblasts and other immunologic cells. When the level of MMPs, MT-MMPs and ADAMTS rises, the balance between MMPs and their
inhibitors can be disturbed. An excess of MMPs can lead to degradation of collagenous tissue in scleritis, as well as in relapsing polychondritis, and in rheumatoid
arthritis. Inhibition of MMPs may be provided in several ways. At first, inhibition of pro-inflammatory cytokines, and immunological cells. Secondly, direct inhibition
of MMPs, and finally, the inhibition of signal transduction pathways.DMARDs: Disease modifying anti-rheumatic drugs; IL-1: interleukine-1; IL-6: interleukine-6;
TNFα: tumor necrosis factor alpha; IL-17: interleukine 17; MMP: matrix metalloproteinase; ADAMTS: a disintegrin and metalloproteinase with thrombospondin
motifs (aggrecanase); MT-MMP: membrane-type MMP; TIMP: tissue inhibitor of matrix metalloproteinase; TGFβ: Transforming growth factor β.
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9.1. Anterior segment of the sclera
In inflamed anterior scleral tissue hypo-reflectivity and small inner
hypo-reflective spaces were found using both UBM and OCT (Fig. 4).
Possible explanations for these hypo-reflective spaces include the in-
filtration of inflammatory cells, edema, or the unraveling of collagen
fibrils, which has been shown in a histopathological evaluations
(Christakopoulos, 2017; Heiligenhaus et al., 1998; Kuroda et al., 2017;
Shoughy et al., 2015; Watson and Young, 1985; Zur et al., 2016).
Thickening of episcleral and scleral tissue in scleritis was repeatedly
described. However, a recent study noticed that the thickening was
mainly due to a thickened episcleral layer (Fig. 4) (Kuroda et al., 2017).
Focusing on the vasculature, FAG and ICG show differences between
scleritis subtypes. Diffuse scleritis, which is characterized by diffuse
hyperemia of (epi)scleral vasculature and pain, showed extensive
leakage of fluorescein on FAG and late leakage on ICG. This implicates
an increased permeability of (epi)scleral vasculature. Nodular scleritis
is clinically characterized by a single, or multiple hyperemic scleral
noduli. ICG showed leakage of the inflamed nodule, and in one patient
the intensity, and size of leakage corresponded with clinical condition.
Dilated vessels in the inflamed scleral noduli were seen in all patients
with FAG, while leakage pattern of the noduli varied (Nieuwenhuizen
et al., 2003; Watson and Romano, 2014). Necrotizing scleritis is char-
acterized by thinning of the inflamed scleral matrix. In this subtype a
sluggish flow, vascular closure, and vascular obliteration in regions of
necrosis were observed with FAG and ICG. Histopathological evidence
of vasculitis was previously reported. Nevertheless, the mechanism of
vascular damage in scleritis remains unclear.
9.2. Posterior segment of the sclera
B-scan US is commonly used to diagnose posterior scleritis. Sclero-
choroidal thickening with high internal reflectivity, and in some cases
fluid in Tenon's capsule, the well-known T-sign, can be seen (Agrawal
et al., 2016; Biswas et al., 1998; Munk et al., 1993; Okhravi et al., 2005;
Wakefield et al., 2013b). MRI can also accurately document scleral
enhancement and thickening. OCT showed that the thickening of the
posterior wall was preferably due to choroidal thickening (Uchihori
et al., 2014). Choroidal involvement was also reported by irregular and
delayed choroidal perfusion, and intermediate-/late phase hyper-
fluorescence at ICG, which was responsive to therapy (Auer and
Herbort, 1998). Whether the choroid is the site of initiation, or chor-
oidal inflammation is adjacent to scleral inflammation, remains un-
known (Watson and Romano, 2014).
10. Lessons from therapeutic options
The corner stone of the treatment of non-infectious scleritis is im-
munosuppressive therapy. As a first step patients are treated with non-
steroidal anti-inflammatory drugs. A second step is the temporary use of
prednisone and/or treatment with disease modifying anti-rheumatic
drugs. Methotrexate and mycophenolate mofetil (MMF) were
considered to be superior compared to azathioprine. Methotrexate en-
hances T-cell apoptosis and affects cytokine production, while MMF
reduces T-cell and B-cell proliferation, antibody production, and leu-
cocyte transmigration. Azathioprine is an inhibitor of the proliferation
of circulating T-cells and B-cells (Beardsley et al., 2013; Daniel Diaz
et al., 2016). In addition, cyclosporine, a T-cell replication inhibitor,
was reported to be effective. As a third step biologicals and small mo-
lecules have enriched the treatment options for scleritis by engaging
specific cytokines, cytokine receptors, or cytokine signaling. Several
inhibitors of the cytokine TNFα (infliximab, adalimumab) showed
beneficial results in small cohorts (de Fidelix et al., 2015). More re-
cently, anti-IL-6R (tocilizumab), anti-IL-1R (anakinra), anti-IL-1β (ge-
vokizumab), and anti-JAK1/3 (tofacitinib) showed effectivity in in-
dividual patients (Bottin et al., 2018; Knickelbein et al., 2016; Poelman
et al., 2019). Furthermore, anti-CD20 therapy (rituximab) provided
positive results, especially in patients with systemic vasculitis (Cao
et al., 2016; de Fidelix et al., 2015; You et al., 2018). The effect of anti-
CD20 therapy suggest a prominent role of B-cells and the adaptive
immune system in the pathogenesis of scleritis, which is supported by
the recent recognition of IgG4 related disease in scleritis (Karim et al.,
2017b). However, the previously mentioned treatment options engage
either T-cells, B-cells or cytokines, suggesting involvement of both
adaptive and innate immunity in the pathogenesis of scleritis.
10.1. Novel therapeutic options engaging MMPs
MMPs are potentially responsible for severe necrosis, and in con-
sequence, their inhibition is of interest. Much effort has been put in
attempts to engineer synthetic MMP inhibitors, especially in patients
with cancer to prevent tumor progression and metastasis (Burrage
et al., 2006). However, the effect of synthetic MMP inhibitors in clinical
studies was so far disappointing. Interestingly, blockage of in-
flammatory cells and cytokines could also potentially reduce the pro-
duction of MMPs (Fig. 3). The anti-TNF inhibitor etanercept has shown
to significantly reduce MMP-1 and MMP-9 levels in rheumatoid ar-
thritis and juvenile idiopathic arthritis patients. Adalimumab has
shown to decrease the levels of proMMP-1 and proMMP-3 in patients
with rheumatoid arthritis (Arends et al., 2011; Basic et al., 2010;
Burrage et al., 2006; Catrina et al., 2002; Chen et al., 2019; Weinblatt
et al., 2003). The precise data on the effect of anti-TNF therapy, as well
as other potential inhibitors of the MMP cascade, are currently lacking
in scleritis (Fig. 3).
11. Discussion and conclusion
This review provides up-to-date insight on the pathogenesis of
scleritis. We reviewed the currently available knowledge on the origin
and maintenance of scleral inflammation, while taking into account
new insights from the research field of systemic autoimmune diseases
associated with scleritis. Research in this field remains challenging
because of the lack of animal models, the scarcity of available human
tissue samples, and low prevalence of the disease.
Fig. 4. Optical coherence tomography (OCT) of the anterior segment in a patient with active anterior scleritis. (Epi)scleral thickening, and small inner scleral
hyporeflective spaces were reported.
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A crucial role for the immune system in the development of non-
infectious scleritis is established. Local inflammation of the sclera to-
gether with increased inflammatory factors in blood and tears are ob-
served, as well as beneficial responses to immunosuppressive treatment
(Palexas et al., 1992; Sainz-de-la-Maza et al., 2016b; Seo et al., 2006).
Additional information may arise from knowledge of specific in-
flammatory processes involved in systemic autoimmune diseases, that
are commonly associated with scleritis. The knowledge of HLA and non-
HLA gene loci revealed overlap of susceptibility genes in systemic au-
toimmune diseases and idiopathic scleritis (Deng and Tsao, 2017;
Karami et al., 2019; Li et al., 2019; Relle et al., 2016). The potential
destructive power of MMPs was studied more extensively in rheumatoid
arthritis. MMP-8 may be a key substance in degrading collagen type 1, a
major substance of scleral tissue, and the importance of ADAMTS and
specific MMPs in the degradation of extracellular matrix PGs was re-
vealed (Burrage et al., 2006). In rheumatoid arthritis, the first attempts
to therapeutically target MMPs are performed (Di Girolamo et al., 1997;
Seo et al., 2006; Young et al., 2004). However, the pathogenic role of
MMPs in scleritis was not yet systematically investigated (Burrage et al.,
2006; Rose and Kooyman, 2016).
Although the insight in the pathogenesis of scleritis has improved
over the last years, several questions remain unanswered. At first, why
does inflammation occur in the sclera, a tissue which is scarcely vas-
cularized? The oscillating blood flow in the suprachoroidal space, re-
sulting from the vascular anastomoses of the choroidal network, pro-
vides a likely place for inflammation. It is thereby proposed, and might
be the origin of scleral inflammation (Watson and Romano, 2014).
Secondly, why does scleritis occur together with systemic autoimmune
diseases? A possible explanation is the similar genetic predisposition
and/or antigenic similarity between scleral tissue and affected tissues of
other organs involved in autoimmune diseases, resulting in so called
mimicry hypothesis. The shared components (such as specific collagens
and proteoglycans) present in affected tissue may be point of im-
munological attack and reason for co-occurrence (Orr et al., 2017). As a
third, why would some patients with scleritis develop severe necrosis of
scleral and adjacent corneal tissue? The collagen destruction is thought
to be due to MMPs, however, as previously mentioned, these enzymes
are not yet systematically studied in scleritis.
Future research directions
Future investigations in the pathogenesis of scleritis are highly re-
commended, and include the following subjects of interest. The iden-
tification of autoantibodies and/or autoreactive T-cells, and the un-
derstanding of the role of MMPs in scleritis. The investigation of gene
loci conferring genetic susceptibility may reveal insight in the patho-
genesis, and may also provide prognostic information. The assessment
of clinically relevant biomarkers in scleritis, and associated systemic
autoimmune diseases, and the improvement of imaging techniques may
reveal additional information of the disease process, therefore they may
improve the clinical management of scleritis. Finally, the development
of accurate animal models would be highly relevant, as these are often
required to validate hypotheses on pathogenesis. The understanding of
the pathogenesis of scleritis has direct implications on its treatment,
and might improve therapy, and visual prognosis of this severe and
disabling ocular disorder.
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